In 2017, the Canadian cannabis industry was getting ready for the country’s anticipated legalization of recreational cannabis. The chief executive officer of Canopy Growth Corporation needed to make decisions about international expansion in the midst of the company’s aggressive expansion activities, which were already underway in Canada. Other Canadian licensed producers were also engaging in international activities in Germany, Chile, Australia, and other countries where cannabis was recently legalized, either for medical or recreational use. Was it time for Canopy Growth Corporation to focus on the Canadian market, or were the international opportunities too good to miss?

In 2017, the Canadian cannabis industry was getting ready for the country's anticipated legalization of recreational cannabis. The chief executive officer of Canopy Growth Corporation needed to make decisions about international expansion in the midst of the company's aggressive expansion activities, which were already underway in Canada. Other Canadian licensed producers were also engaging in international activities in Germany, Chile, Australia, and other countries where cannabis was recently legalized, either for medical or recreational use. Was it time for Canopy Growth Corporation to focus on the Canadian market, or were the international opportunities too good to miss?

OrganiGram Holdings Inc. (OrganiGram), a New Brunswick-based company, was a licensed producer of medical cannabis in Canada. On April 20, 2016, the Canadian government announced that legislation to legalize recreational cannabis would be introduced in the spring of 2017 with the intention of having it become law in the spring of 2018. The announcement triggered expansion activities at all of Canada’s largest licensed producers of cannabis. However, there were many unknowns in terms of how the legalization of recreational cannabis would happen. What would the timeline be? Who would be allowed to grow cannabis? In anticipation of regulatory changes, OrganiGram needed to analyze the Canadian cannabis industry and engage in a scenario-planning exercise. How could OrganiGram move through this time of uncertainty, while both creating a strategy for the anticipated recreational cannabis market and continuing to work on its medical cannabis sales?

OrganiGram Holdings Inc. (OrganiGram), a New Brunswick-based company, was a licensed producer of medical cannabis in Canada. On April 20, 2016, the Canadian government announced that legislation to legalize recreational cannabis would be introduced in the spring of 2017 with the intention of having it become law in the spring of 2018. The announcement triggered expansion activities at all of Canada's largest licensed producers of cannabis. However, there were many unknowns in terms of how the legalization of recreational cannabis would happen. What would the timeline be? Who would be allowed to grow cannabis? In anticipation of regulatory changes, OrganiGram needed to analyze the Canadian cannabis industry and engage in a scenario-planning exercise. How could OrganiGram move through this time of uncertainty, while both creating a strategy for the anticipated recreational cannabis market and continuing to work on its medical cannabis sales?